The genetic polymorphisms of the cytochrome P450 may influence on the metabolism of tamoxifen. The investigators want to * evaluate the frequency or incidence of the genetic polymorphisms of cytochrome P450 subfamilies(CYP2D6, CYP3A4/5 and CYP2C19) in breast cancer patients, and * analyze the association between the genetic polymorphisms of cytochrome P450 subfamilies and clinical outcomes in breast cancer patients treated by adjuvant tamoxifen therapy.
Study Type
OBSERVATIONAL
Department of Pharmacology and Pharmacogenomics Research Center, Inje University College of Medicine
Jin-Gu, Busan, South Korea
Department of Surgery, Yonsei University College of Medicine
Saedaemoon-gu, Seoul, South Korea
The frequency of the genetic polymorphisms of CYP2D6 in breast cancer patients
The frequency of the genetic polymorphisms of CYP3A4/5 in breast cancer patients
The frequency of the genetic polymorphisms of CYP2C19 in breast cancer patients
The association between the genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen therapy
The association between the genetic polymorphisms of CYP3A4/5 and outcomes in breast cancer patients with tamoxifen therapy
The association between the genetic polymorphisms of CYP2C19 and outcomes in breast cancer patients with tamoxifen therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.